Medicine / Medicine - Oncology

DUMC 102002
Durham, NC 27710

919-668-8108

919-668-4667

919-660-0178

• MD, University of Virginia School of Medicine, 2000

• Internal Medicine, Hospital of the University of Pennsylvania, 2000-2003

• Medical Oncology, Johns Hopkins Hospital (Maryland), 2003-2006

• MSc, Clinical Investigation, Johns Hopkins School of Public Health (Maryland), 2007

Drug development and novel strategies for the treatment and management of advanced prostate cancer and other GU malignancies; targeted therapy; PI3 kinase inhibitor; novel hormonal and immune therapies; targeted therapies; predictive biomarkers; prognostic and surrogate models in GU malignancies; perioperative biologic therapeutics; circulating tumor-cell biology

1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition

• Whang, YE; Armstrong, AJ; Rathmell, WK; Godley, PA; Kim, WY; Pruthi, RS; Wallen, EM; Crane, JM; Moore, DT; Grigson, G; Morris, K; Watkins, CP; George, DJ. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urologic Oncology: seminars and original investigations. 2013;31:82-86.  Abstract
• Araujo, JC; Mathew, P; Armstrong, AJ; Braud, EL; Posadas, E; Lonberg, M; Gallick, GE; Trudel, GC; Paliwal, P; Agrawal, S; Logothetis, CJ. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer. 2012;118:63-71.  Abstract
• Armstrong, AJ; Eisenberger, MA; Halabi, S; Oudard, S; Nanus, DM; Petrylak, DP; Sartor, AO; Scher, HI. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. European Urology. 2012;61:549-559.  Abstract
• Pond, GR; Armstrong, AJ; Wood, BA; Brookes, M; Leopold, L; Berry, WR; de Wit, R; Eisenberger, MA; Tannock, IF; Sonpavde, G. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. European Urology. 2012;61:363-369.  Abstract
• Sonpavde, G; Pond, GR; Berry, WR; de Wit, R; Armstrong, AJ; Eisenberger, MA; Tannock, IF. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urologic Oncology: seminars and original investigations. 2012;30:607-613.  Abstract
• Stewart, SB; Bañez, LL; Robertson, CN; Freedland, SJ; Polascik, TJ; Xie, D; Koontz, BF; Vujaskovic, Z; Lee, WR; Armstrong, AJ; Febbo, PG; George, DJ; Moul, JW. Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center. Journal of Urology. 2012;187:103-108.  Abstract
• Antonarakis, ES; Armstrong, AJ. Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 2011;14:206-218.  Abstract
• Antonarakis, ES; Armstrong, AJ. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 2011;14:192-205.  Abstract
• Armstrong, AJ; Marengo, MS; Oltean, S; Kemeny, G; Bitting, RL; Turnbull, JD; Herold, CI; Marcom, PK; George, DJ; Garcia-Blanco, MA. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Molecular Cancer Research. 2011;9:997-1007.  Abstract
• Bitting, RL; Armstrong, AJ; George, DJ. Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?. Clinical Medicine Insights: Oncology. 2011;5:325-332.  Abstract
• Bitting, RL; Madden, J; Armstrong, AJ. Therapy for non-clear cell histologies in renal cancer. Current Clinical Pharmacology. 2011;6:169-180.  Abstract
• Pili, R; Häggman, M; Stadler, WM; Gingrich, JR; Assikis, VJ; Björk, A; Nordle, O; Forsberg, G; Carducci, MA; Armstrong, AJ. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. Journal of Clinical Oncology. 2011;29:4022-4028.  Abstract
• Sonpavde, G; Pond, GR; Berry, WR; de Wit, R; Eisenberger, MA; Tannock, IF; Armstrong, AJ. The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer. 2011;117:3963-3971.  Abstract
• Armstrong, AJ; Garrett-Mayer, E; de Wit, R; Tannock, I; Eisenberger, M. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clinical Cancer Research. 2010;16:203-211.  Abstract
• Armstrong, AJ; George, DJ. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. Prostate Cancer and Prostatic Diseases. 2010;13:108-116.  Abstract
• Armstrong, AJ; Netto, GJ; Rudek, MA; Halabi, S; Wood, DP; Creel, PA; Mundy, K; Davis, SL; Wang, T; Albadine, R; Schultz, L; Partin, AW; Jimeno, A; Fedor, H; Febbo, PG; George, DJ; Gurganus, R; De Marzo, AM; Carducci, MA. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clinical Cancer Research. 2010;16:3057-3066.  Abstract
• Armstrong, AJ; Tannock, IF; de Wit, R; George, DJ; Eisenberger, M; Halabi, S. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. European Journal of Cancer. 2010;46:517-525.  Abstract
• Armstrong, AJ; Febbo, PG. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. The Oncologist. 2009;14:816-827.  Abstract
• Armstrong, AJ; Halabi, S; de Wit, R; Tannock, IF; Eisenberger, M. The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. Prostate Cancer and Prostatic Diseases. 2009;12:88-93.  Abstract
• Armstrong, AJ; Creel, P; Turnbull, J; Moore, C; Jaffe, TA; Haley, S; Petros, W; Yenser, S; Gockerman, JP; Sleep, D; Hurwitz, H; George, DJ. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clinical Cancer Research. 2008;14:6270-6276.  Abstract
• Armstrong, AJ; Garrett-Mayer, EL; Eisenberger, M. Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. Journal of National Cancer Institute. 2008;100:681-682.  Abstract
• Armstrong, AJ; George, DJ. New drug development in metastatic prostate cancer. Urologic Oncology: seminars and original investigations. 2008;26:430-437.  Abstract
• Chen, FL; Armstrong, AJ; George, DJ. Cell signaling modifiers in prostate cancer. The Cancer Journal. 2008;14:40-45.  Abstract
• Figlin, RA; Brown, E; Armstrong, AJ; Akerley, W; Benson, AB; Burstein, HJ; Ettinger, DS; Febbo, PG; Fury, MG; Hudes, GR; Kies, MS; Kwak, EL; Morgan, RJ; Mortimer, J; Reckamp, K; Venook, AP; Worden, F; Yen, Y. NCCN Task Force Report: mTOR inhibition in solid tumors. Journal of the National Comprehensive Cancer Network : JNCCN. 2008;6 Suppl 5:S1-20.  Abstract
• Ramiah, V; George, DJ; Armstrong, AJ. Clinical endpoints for drug development in prostate cancer. Current Opinion in Urology. 2008;18:303-308.  Abstract
• Armstrong, AJ; Febbo, PG; George, DJ; Moul, J. Systemic strategies for prostate cancer. Minerva Urologica e Nefrologica. 2007;59:11-25.  Abstract
• Armstrong, AJ; Garrett-Mayer, E; Ou Yang, YC; Carducci, MA; Tannock, I; de Wit, R; Eisenberger, M. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology. 2007;25:3965-3970.  Abstract
• Armstrong, AJ; Garrett-Mayer, ES; Yang, YC; de Wit, R; Tannock, IF; Eisenberger, M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clinical Cancer Research. 2007;13:6396-6403.  Abstract
• Mendiratta, P; Armstrong, AJ; George, DJ. Current standard and investigational approaches to the management of hormone-refractory prostate cancer. Reviews in Urology. 2007;9 Suppl 1:S9-S19.  Abstract
• Srinivasan, R; Armstrong, AJ; Dahut, W; George, DJ. Anti-angiogenic therapy in renal cell cancer. British Journal of Urology (BJU) International. 2007;99:1296-1300.  Abstract
• Armstrong, AJ; Carducci, MA. New drugs in prostate cancer. Current Opinion in Urology. 2006;16:138-145.  Abstract
• Armstrong, AJ; Eisenberger, M. Does gonadotropin-releasing-hormone agonist therapy for prostate cancer increase the risk of fracture?. Nature Reviews: Urology. 2006;3:246-247.  Abstract
• Armstrong, AJ; Carducci, MA. Advanced prostate cancer: the future. Canadian Journal of Urology. 2005;12 Suppl 2:42-47.  Abstract
• Armstrong, AJ; Carducci, MA. Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies. Current Oncology Reports. 2005;7:220-227.  Abstract
• Armstrong, AJ; Carducci, MA. Novel therapeutic approaches to advanced prostate cancer. Clinical Advances in Hematology and Oncology. 2005;3:271-282.  Abstract
• Nightingale, RW; Camacho, DL; Armstrong, AJ; Robinette, JJ; Myers, BS. Inertial properties and loading rates affect buckling modes and injury mechanisms in the cervical spine. Journal of Biomechanics. 2000;33:191-197.  Abstract
• Fukasawa, K; Zhou, R; Matten, WT; Armstrong, AJ; Daar, I; Oskarsson, M; Sathyanarayana, BK; Maclvor, L; Wood, TG; Vande Woude, GF. Mutagenic analysis of functional domains of the mos proto-oncogene and identification of the sites important for MAPK activation and DNA binding. Oncogene. 1995;11:1447-1457.  Abstract